Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Serigstad, S, Markussen, D, Grewal, HMS, Ebbesen, M, Kommedal, Heggelund, L, van Werkhoven, CH, Faurholt-Jepsen, D, Clark, TW, Ritz, C, Ulvestad, E, Bjørneklett, R, Knoop, ST & The CAPNOR Study Group 2022, 'Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield', Scientific Reports, bind 12, nr. 1, 326. https://doi.org/10.1038/s41598-021-03741-7

APA

Serigstad, S., Markussen, D., Grewal, H. M. S., Ebbesen, M., Kommedal, Heggelund, L., van Werkhoven, C. H., Faurholt-Jepsen, D., Clark, T. W., Ritz, C., Ulvestad, E., Bjørneklett, R., Knoop, S. T., & The CAPNOR Study Group (2022). Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. Scientific Reports, 12(1), [326]. https://doi.org/10.1038/s41598-021-03741-7

CBE

Serigstad S, Markussen D, Grewal HMS, Ebbesen M, Kommedal, Heggelund L, van Werkhoven CH, Faurholt-Jepsen D, Clark TW, Ritz C, Ulvestad E, Bjørneklett R, Knoop ST, The CAPNOR Study Group. 2022. Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. Scientific Reports. 12(1):Article 326. https://doi.org/10.1038/s41598-021-03741-7

MLA

Vancouver

Author

Serigstad, S. ; Markussen, D. ; Grewal, H. M.S. ; Ebbesen, M. ; Kommedal ; Heggelund, L. ; van Werkhoven, C. H. ; Faurholt-Jepsen, D. ; Clark, T. W. ; Ritz, C. ; Ulvestad, E. ; Bjørneklett, R. ; Knoop, S. T. ; The CAPNOR Study Group. / Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. I: Scientific Reports. 2022 ; Bind 12, Nr. 1.

Bibtex

@article{694ffcd2c8584689bf361ea31727222e,
title = "Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield",
abstract = "Lack of rapid and comprehensive microbiological diagnosis in patients with community acquired pneumonia (CAP) hampers appropriate antimicrobial therapy. This study evaluates the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) and explores the feasibility of evaluation in a randomised controlled trial. Patients presenting to hospital with suspected CAP were recruited in a prospective feasibility study. An induced sputum or an endotracheal aspirate was obtained from all participants. The FAP plus turnaround time (TAT) and microbiological yield were compared with standard diagnostic methods (SDs). 96/104 (92%) enrolled patients had a respiratory tract infection (RTI); 72 CAP and 24 other RTIs. Median TAT was shorter for the FAP plus, compared with in-house PCR (2.6 vs 24.1 h, p < 0.001) and sputum cultures (2.6 vs 57.5 h, p < 0.001). The total microbiological yield by the FAP plus was higher compared to SDs (91% (162/179) vs 55% (99/179), p < 0.0001). Haemophilus influenzae, Streptococcus pneumoniae and influenza A virus were the most frequent pathogens. In conclusion, molecular panel testing in adults with CAP was associated with a significant reduction in time to actionable results and increased microbiological yield. The impact on antibiotic use and patient outcome should be assessed in randomised controlled trials.",
author = "S. Serigstad and D. Markussen and Grewal, {H. M.S.} and M. Ebbesen and Kommedal and L. Heggelund and {van Werkhoven}, {C. H.} and D. Faurholt-Jepsen and Clark, {T. W.} and C. Ritz and E. Ulvestad and R. Bj{\o}rneklett and Knoop, {S. T.} and R. Bj{\o}rneklett and Clark, {T. W.} and M. Ebbesen and D. Faurholt-Jepsen and Grewal, {H. M.S.} and L. Heggelund and Knoop, {S. T.} and Kommedal and D. Markussen and P. Ravn and C. Ritz and S. Serigstad and E. Ulvestad and {van Werkhoven}, {C. H.} and {The CAPNOR Study Group}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41598-021-03741-7",
language = "English",
volume = "12",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield

AU - Serigstad, S.

AU - Markussen, D.

AU - Grewal, H. M.S.

AU - Ebbesen, M.

AU - Kommedal,

AU - Heggelund, L.

AU - van Werkhoven, C. H.

AU - Faurholt-Jepsen, D.

AU - Clark, T. W.

AU - Ritz, C.

AU - Ulvestad, E.

AU - Bjørneklett, R.

AU - Knoop, S. T.

AU - Bjørneklett, R.

AU - Clark, T. W.

AU - Ebbesen, M.

AU - Grewal, H. M.S.

AU - Heggelund, L.

AU - Knoop, S. T.

AU - Kommedal,

AU - Markussen, D.

AU - Ritz, C.

AU - Serigstad, S.

AU - Ulvestad, E.

AU - van Werkhoven, C. H.

AU - The CAPNOR Study Group

A2 - Faurholt-Jepsen, D.

A2 - Ravn, P.

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - Lack of rapid and comprehensive microbiological diagnosis in patients with community acquired pneumonia (CAP) hampers appropriate antimicrobial therapy. This study evaluates the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) and explores the feasibility of evaluation in a randomised controlled trial. Patients presenting to hospital with suspected CAP were recruited in a prospective feasibility study. An induced sputum or an endotracheal aspirate was obtained from all participants. The FAP plus turnaround time (TAT) and microbiological yield were compared with standard diagnostic methods (SDs). 96/104 (92%) enrolled patients had a respiratory tract infection (RTI); 72 CAP and 24 other RTIs. Median TAT was shorter for the FAP plus, compared with in-house PCR (2.6 vs 24.1 h, p < 0.001) and sputum cultures (2.6 vs 57.5 h, p < 0.001). The total microbiological yield by the FAP plus was higher compared to SDs (91% (162/179) vs 55% (99/179), p < 0.0001). Haemophilus influenzae, Streptococcus pneumoniae and influenza A virus were the most frequent pathogens. In conclusion, molecular panel testing in adults with CAP was associated with a significant reduction in time to actionable results and increased microbiological yield. The impact on antibiotic use and patient outcome should be assessed in randomised controlled trials.

AB - Lack of rapid and comprehensive microbiological diagnosis in patients with community acquired pneumonia (CAP) hampers appropriate antimicrobial therapy. This study evaluates the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) and explores the feasibility of evaluation in a randomised controlled trial. Patients presenting to hospital with suspected CAP were recruited in a prospective feasibility study. An induced sputum or an endotracheal aspirate was obtained from all participants. The FAP plus turnaround time (TAT) and microbiological yield were compared with standard diagnostic methods (SDs). 96/104 (92%) enrolled patients had a respiratory tract infection (RTI); 72 CAP and 24 other RTIs. Median TAT was shorter for the FAP plus, compared with in-house PCR (2.6 vs 24.1 h, p < 0.001) and sputum cultures (2.6 vs 57.5 h, p < 0.001). The total microbiological yield by the FAP plus was higher compared to SDs (91% (162/179) vs 55% (99/179), p < 0.0001). Haemophilus influenzae, Streptococcus pneumoniae and influenza A virus were the most frequent pathogens. In conclusion, molecular panel testing in adults with CAP was associated with a significant reduction in time to actionable results and increased microbiological yield. The impact on antibiotic use and patient outcome should be assessed in randomised controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=85122873570&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-03741-7

DO - 10.1038/s41598-021-03741-7

M3 - Journal article

C2 - 35013351

AN - SCOPUS:85122873570

VL - 12

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 326

ER -

ID: 79245445